Kailera Therapeutics, Inc. Payments to Acquire Marketable Securities
Kailera Therapeutics, Inc. (KLRA) reported Payments to Acquire Marketable Securities of $738.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-12
- Kailera Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $689.81M, a 739.47% increase year-over-year.
- Kailera Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $48.45M, a 11.01% decline year-over-year.
- Kailera Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-06-30 was $82.17M.
- Kailera Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-03-31 was $54.44M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month |
|---|---|---|
| 2026-06-30 | $689.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $738.26M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $48.45M 10-Q · filed 2026-05-26 | |
| 2025-06-30 | $82.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $136.61M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $54.44M 10-Q · filed 2026-05-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |